Literature DB >> 12388277

Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine.

Jason Peart1, Laura Willems, John P Headrick.   

Abstract

The relative roles of mitochondrial (mito) ATP-sensitive K(+) (mitoK(ATP)) channels, protein kinase C (PKC), and adenosine kinase (AK) in adenosine-mediated protection were assessed in Langendorff-perfused mouse hearts subjected to 20-min ischemia and 45-min reperfusion. Control hearts recovered 72 +/- 3 mmHg of ventricular pressure (50% preischemia) and released 23 +/- 2 IU/g lactate dehydrogenase (LDH). Adenosine (50 microM) during ischemia-reperfusion improved recovery (149 +/- 8 mmHg) and reduced LDH efflux (5 +/- 1 IU/g). Treatment during ischemia alone was less effective. Treatment with 50 microM diazoxide (mitoK(ATP) opener) during ischemia and reperfusion enhanced recovery and was equally effective during ischemia alone. A(3) agonism [100 nM 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide], A(1) agonism (N(6)-cyclohexyladenosine), and AK inhibition (10 microM iodotubercidin) all reduced necrosis to the same extent as adenosine, but less effectively reduced contractile dysfunction. These responses were abolished by 100 microM 5-hydroxydecanoate (5-HD, mitoK(ATP) channel blocker) or 3 microM chelerythrine (PKC inhibitor). However, the protective effects of adenosine during ischemia-reperfusion were resistant to 5-HD and chelerythrine and only abolished when inhibitors were coinfused with iodotubercidin. Data indicate adenosine-mediated protection via A(1)/A(3) adenosine receptors is mitoK(ATP) channel and PKC dependent, with evidence for a downstream location of PKC. Adenosine provides additional and substantial protection via phosphorylation to 5'-AMP, primarily during reperfusion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388277     DOI: 10.1152/ajpheart.00717.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  9 in total

Review 1.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

2.  Oxidant stress and damage in post-ischemic mouse hearts: effects of adenosine.

Authors:  Benjamin Hack; Paul K Witting; Benjamin S Rayner; Roland Stocker; John P Headrick
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

3.  Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction.

Authors:  John Fassett; Xin Xu; Dongmin Kwak; Guangshuo Zhu; Erin K Fassett; Ping Zhang; Huan Wang; Bernd Mayer; Robert J Bache; Yingjie Chen
Journal:  J Mol Cell Cardiol       Date:  2019-03-22       Impact factor: 5.000

Review 4.  Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion.

Authors:  Giancarlo Solaini; David A Harris
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

Review 5.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

6.  Remifentanil-induced preconditioning has cross-talk with A1 and A2B adenosine receptors in ischemic-reperfused rat heart.

Authors:  Yong-Cheol Lee; Jiyoon Jung; Sang-Jin Park
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

7.  Endogenous adenosine selectively modulates oxidant stress via the A1 receptor in ischemic hearts.

Authors:  Melissa E Reichelt; Anu Shanu; Laura Willems; Paul K Witting; Natasha A Ellis; Michael R Blackburn; John P Headrick
Journal:  Antioxid Redox Signal       Date:  2009-11       Impact factor: 8.401

8.  The effect of adenosine deaminase inhibition on the A1 adenosinergic and M2 muscarinergic control of contractility in eu- and hyperthyroid guinea pig atria.

Authors:  Krisztian Pak; Judit Zsuga; Zita Kepes; Tamas Erdei; Balazs Varga; Bela Juhasz; Andras Jozsef Szentmiklosi; Rudolf Gesztelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-04-16       Impact factor: 3.000

9.  Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model.

Authors:  Jesper van der Pals; Sasha Koul; Michael I Götberg; Göran K Olivecrona; Martin Ugander; Mikael Kanski; Andreas Otto; Matthias Götberg; Håkan Arheden; David Erlinge
Journal:  BMC Cardiovasc Disord       Date:  2010-01-04       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.